Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Specialized Medical Company (4019.SR)
Riyadh, SA
Based in Riyadh, Saudi Arabia, and established in 1994, Specialized Medical Company operates an extensive network of hospitals, clinics, and medical centers throughout the Kingdom. Its diverse activities are categorized into two primary segments: Medical Services, and Pharmacies & Other Offerings. The company delivers a full spectrum of medical care, encompassing both diagnostic and therapeutic treatments across numerous specialties. These include urgent care, cardiology, internal and family medicine, and pediatrics. Essential ancillary services are also provided, such as laboratory diagnostics (including histopathology), advanced imaging (radiology and nuclear medicine), anesthesiology, pharmaceutical supply, and physiotherapy rehabilitation. Furthermore, Specialized Medical Company boasts comprehensive surgical capabilities, with specialized units for operating rooms, post-operative recovery, maternity (delivery), ophthalmology, general surgery, obstetrics and gynecology, urology, orthopedics, and ear, nose, and throat (ENT) procedures. Critical care is a key offering, featuring specialized intensive care units for neonates (NICU), cardiac patients (CCU), and general critical conditions (ICU). Beyond conventional medicine, the company extends its portfolio to include dermatology, anti-aging, aesthetic services, home healthcare, virtual consultations, and dentistry. In addition to its healthcare provisions, the company's "Pharmacies & Other" segment encompasses a range of services such as the provision of prepared and unprepared food, maintenance for hospital and other facilities, and the management and operation of restaurants, alongside other non-medical, healthy food, and food-related enterprises.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -8.69% | -8.39% | -9.72% | -7.37% | -30.84% | -30.84% | -30.84% | -30.84% | -30.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+5.1% Q3'25: -2.2% (vs Q3'24)
-
EPS growth Medical - Care Facilities: +19.2%+11.1% Q3'25: +12.5% (vs Q3'24)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+14.6% ★ Q3'25: +22.2% (vs Q3'24)
-
EBIT margin Medical - Care Facilities: +11.3%+16.6% ★ Q3'25: +21.1% (vs Q3'24)
-
ROIC Medical - Care Facilities: +6.8%+12.7% ★ Q3'25: +18.7% (vs Q3'24)
-
Share dilution Medical - Care Facilities: +0.0%+0.0% Q3'25: +0.0% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×3.26× Q3'25: 2.13× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
1.63B
est.
|
1.60B
1.60B – 1.60B
-1.5% YoY
|
1.81B
1.81B – 1.81B
+12.9% YoY
|
| EBITDA |
511.54M
est.
|
503.69M
503.69M – 503.69M
-1.5% YoY
|
568.69M
568.69M – 568.69M
+12.9% YoY
|
| EBIT |
499.65M
est.
|
491.99M
491.99M – 491.99M
-1.5% YoY
|
555.48M
555.48M – 555.48M
+12.9% YoY
|
| Net Income |
245.00M
est.
|
225.00M
225.00M – 225.00M
-8.2% YoY
|
275.00M
275.00M – 275.00M
+22.2% YoY
|
| SGA |
188.11M
est.
|
185.23M
185.23M – 185.23M
-1.5% YoY
|
209.13M
209.13M – 209.13M
+12.9% YoY
|
| EPS |
0.98
est.
|
0.90
0.90 – 0.90
-8.2% YoY
|
1.10
1.10 – 1.10
+22.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-17 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-10 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-03 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-26 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-19 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Saudi Arabia ETF KSA | 0.13% | 833.1K | 0.75% |
| 2 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.02% | 71.9K | 0.72% |
| 3 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 21.7K | 0.42% |
| 4 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.01% | 49.5K | 0.74% |
| 5 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.01% | 55.4K | 0.55% |
| 6 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 12.9K | 0.33% |
| 7 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 601.3K | 0.33% |
| 8 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 5.3K | 0.35% |
| 9 | iShares Core MSCI EM IMI UCITS ETF EIMU.L | 0.00% | 19.3K | 0.18% |
| 10 | iShares Core MSCI EM IMI UCITS ETF EIMI.L | 0.00% | 469.3K | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Abdullah Aljasir | General Counsel | — | male |
| Bassam Tayseer Chahine | Chief Executive Officer | — | male |
| Elissar Al-Tawil Hamadeh | Chief Supply Chain & Project Officer | — | female |
| Faisal Altimyat | Director of Investor Relations | — | male |
| Hani Charani | Chief Financial Officer | — | male |
| Hassan Zuhair Al Hashem | Head of Marketing Department | — | male |
| Kassem Baalbaki | Chief Information Officer | — | male |
| Khaled Hadi Al Qahtani | Chief Operating Officer | — | male |
| Mohammed Salem Al Saleh | General Counsel | — | male |
| Nasser Saleh Al Luhaidan | Chief Governance, Compliance & Risk Officer | — | male |
| Sadiq Ali Alali | Board Secretary & Director of Investor Relations | — | male |
| Saeed Youssef Ahmed | Chief Nursing Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4019.SR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
